SELLAS Life Sciences Group, Inc.
SLS
$6.29
$1.0720.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.42% | -4.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.02% | 3.06% | |||
| Operating Income | -1.02% | -3.06% | |||
| Income Before Tax | -12.77% | -2.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.77% | -2.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.77% | -2.88% | |||
| EBIT | -1.02% | -3.06% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 13.42% | 6.57% | |||
| Normalized Basic EPS | 26.02% | 6.44% | |||
| EPS Diluted | 13.42% | 10.57% | |||
| Normalized Diluted EPS | 26.02% | 6.44% | |||
| Average Basic Shares Outstanding | 30.32% | 9.98% | |||
| Average Diluted Shares Outstanding | 30.32% | 9.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||